¿Por qué sube el precio de la acción de PFIZER?
Los alcistas dicen
Obesity pipeline
Analyst notes that late-stage data for berobenatide and combination studies could materially expand the obesity franchise and prompt a re-rating of the stock.
Cost savings and margin expansion
Analyst highlights that an expanded cost savings program and manufacturing optimizations are expected to improve margins and operating leverage, supporting earnings resilience.
Prostate cancer Phase 3 readout
Analyst points out that a positive Phase 3 result for mevrometostat could establish a new standard in advanced prostate cancer and generate wholly owned sales that materially boost growth.
COVID product sales pressure
Analyst warns that weaker-than-expected Paxlovid and other COVID product sales have pressured revenue and constrained upside to guidance.
Clinical development risk
Analyst warns that a failed lung cancer study and delayed readouts due to slower event rates raise uncertainty around the pipeline and the timing of key catalysts.
Acquisition and governance uncertainty
Analyst cautions that lingering questions about the Seagen acquisition and an abrupt finance leadership departure increase uncertainty around integration, capital allocation and dividend reliability.
